NEW YORK (GenomeWeb) – Australian diagnostics firm SpeeDx announced on Thursday that it has received CE-IVD marking for a qPCR assay to detect both Neisseria gonorrhoeae and sequences in the gyrA gene of the bacteria linked to ciprofloxacin susceptibility.

According to SpeeDx, the Resistance GC assay will allow doctors to confidently and cost-effectively treat up to 70 percent of gonorrhea infections with a single oral dose of ciprofloxacin.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.